1. Home
  2. RLGT vs ENGN Comparison

RLGT vs ENGN Comparison

Compare RLGT & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Radiant Logistics Inc.

RLGT

Radiant Logistics Inc.

N/A

Current Price

$9.01

Market Cap

416.9M

ML Signal

N/A

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

N/A

Current Price

$1.98

Market Cap

117.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
RLGT
ENGN
Founded
2001
1999
Country
United States
Canada
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
416.9M
117.2M
IPO Year
2006
2023

Fundamental Metrics

Financial Performance
Metric
RLGT
ENGN
Price
$9.01
$1.98
Analyst Decision
Strong Buy
Hold
Analyst Count
3
10
Target Price
★ $11.00
$3.29
AVG Volume (30 Days)
324.7K
★ 662.0K
Earning Date
11-09-2026
09-08-2026
Dividend Yield
N/A
N/A
EPS Growth
11.43
★ 56.85
EPS
★ 0.39
N/A
Revenue
★ $934,356,000.00
N/A
Revenue This Year
$4.96
N/A
Revenue Next Year
$4.98
N/A
P/E Ratio
$22.44
★ N/A
Revenue Growth
★ 3.51
N/A
52 Week Low
$5.82
$1.40
52 Week High
$10.20
$12.25

Technical Indicators

Market Signals
Indicator
RLGT
ENGN
Relative Strength Index (RSI) 51.68 58.34
Support Level $8.68 $1.67
Resistance Level $8.77 $2.08
Average True Range (ATR) 0.33 0.07
MACD 0.01 0.01
Stochastic Oscillator 30.84 71.43

Price Performance

Historical Comparison
RLGT
ENGN

About RLGT Radiant Logistics Inc.

Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services, including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.

About ENGN enGene Holdings Inc.

enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Share on Social Networks: